Latest On Wave Life Sciences Ltd (WVE):
| Date/Time | Type | Description | Signal | Details |
|---|---|---|---|---|
| 2023-05-23 19:33 EST | News | Wave Life Sciences crashes on decision to drop neurology asset on trial setback | N/A |  |
| 2023-05-03 17:10 EST | News | Wave Life Sciences GAAP EPS of -$0.27 misses by $0.23, revenue of $12.93M misses by $25.67M | N/A | |
| 2023-05-03 17:10 EST | News | Wave Life Sciences Ltd. (WVE) Q1 2023 Earnings Call Transcript | N/A | |
| 2023-05-02 16:03 EST | News | Wave Life Sciences Q1 2023 Earnings Preview | N/A | |
| 2023-03-22 19:19 EST | News | Wave Life Sciences GAAP EPS of -$0.47 misses by $0.06, revenue of $1.24M misses by $1.16M | N/A | |
| 2023-03-22 19:18 EST | News | Wave Life Sciences Ltd. 2022 Q4 - Results - Earnings Call Presentation | N/A | |
| 2023-03-22 19:18 EST | News | Wave Life Sciences Ltd (WVE) Q4 2022 Earnings Call Transcript | N/A | |
| 2023-03-21 11:59 EST | News | Wave Life Sciences Q4 2022 Earnings Preview | N/A | |
| 2023-03-13 05:38 EST | News | RAPT Therapeutics, Repare Therapeutics among biotechs to disclose exposure to Silicon Valley Bank | N/A | |
| 2023-01-08 08:22 EST | News | Wave Life Sciences: Huntington's Hypotheses, GSK Collaboration Catalysts To Move The Needle | N/A | |
| 2022-12-13 14:27 EST | News | Wave Life stock surges 20% in team up with GSK for genetic diseases | N/A | |
| 2022-11-11 01:23 EST | News | Wave Life Sciences Ltd. 2022 Q3 - Results - Earnings Call Presentation | N/A | |
| 2022-11-11 01:23 EST | News | Wave Life Sciences Ltd. (WVE) Q3 2022 Earnings Call Transcript | N/A | |
| 2022-11-10 07:50 EST | News | Wave Life Sciences GAAP EPS of -$0.42 beats by $0.08, revenue of $0.29M misses by $5.11M | N/A | |
| 2022-11-09 14:49 EST | News | Wave Life Sciences Q3 2022 Earnings Preview | N/A | |
| 2022-09-21 00:13 EST | News | Wave Life's WVE-003 shows promise in interim data of Huntington's disease trial | N/A | |
| 2022-08-11 17:59 EST | News | Wave Life Sciences GAAP EPS of -$0.62 misses by $0.08, revenue of $0.37M | N/A | |
| 2022-08-11 17:59 EST | News | Wave Life Sciences Ltd. 2022 Q2 - Results - Earnings Call Presentation | N/A | |
| 2022-08-11 17:59 EST | News | Wave Life Sciences Ltd. (WVE) CEO Paul Bolno on Q2 2022 Results - Earnings Call Transcript | N/A | |
| 2022-08-11 01:42 EST | News | Wave Life Sciences Q2 2022 Earnings Preview | N/A | |
| 2022-06-22 10:01 EST | News | Ra Capital Management raises passive stake in Wave Life Sciences | N/A | |
| 2022-06-15 00:46 EST | News | Wave Life Sciences to raise $70M in stock offering | N/A | |
| 2022-05-14 05:36 EST | News | Wave Life Sciences Ltd.'s (WVE) CEO Paul Bolno on Q1 2022 Results - Earnings Call Transcript | N/A | |
| 2022-05-14 05:36 EST | News | Wave Life Sciences slips as H.C. Wainwright lowers target | N/A | |
| 2022-05-13 02:49 EST | News | Wave Life Sciences GAAP EPS of -$0.62 misses by $0.06, revenue of $1.75M misses by $2.11M | N/A | |
| 2022-05-13 02:49 EST | News | Wave Life Sciences Ltd. (WVE) CEO Paul Bolno on Q1 2022 Results - Earnings Call Transcript | N/A | |
| 2022-05-13 02:49 EST | News | Wave Life Sciences Ltd. 2022 Q1 - Results - Earnings Call Presentation | N/A | |
| 2022-05-12 06:46 EST | News | Wave Life Sciences Q1 2022 Earnings Preview | N/A | |
| 2022-04-05 01:08 EST | News | Wave Life gains most in more than a year after early-stage data for ALS drug | N/A | |
| 2022-03-31 02:14 EST | News | Wave Life Sciences (WVE) Investor Presentation - Slideshow | N/A | |
| 2022-03-05 07:12 EST | News | Wave Life Sciences Ltd. 2021 Q4 - Results - Earnings Call Presentation | N/A | |
| 2022-03-03 20:07 EST | News | Wave Life Sciences GAAP EPS of -$0.61 misses by $0.06, revenue of $1.76M misses by $11.98M | N/A | |
| 2022-03-03 20:06 EST | News | Wave Life Sciences Ltd. (WVE) CEO Paul Bolno on Q4 2021 Results - Earnings Call Transcript | N/A | |
| 2022-03-03 02:56 EST | News | Wave Life Sciences Q4 2021 Earnings Preview | N/A | |
| 2022-01-25 21:00 EST | News | Wave Life Sciences' FTD, ALS clinical program to get investment from 2 organizations | N/A | |
| 2021-11-10 18:38 EST | News | Wave Life Sciences EPS beats by $0.52, beats on revenue | N/A | |
| 2021-11-10 18:37 EST | News | Wave Life Sciences Ltd. (WVE) CEO Paul Bolno on Q3 2021 Results - Earnings Call Transcript | N/A | |
| 2021-11-10 18:37 EST | News | Wave Life Sciences Ltd. 2021 Q3 - Results - Earnings Call Presentation | N/A | |
| 2021-11-09 19:57 EST | News | Wave Life Sciences Q3 2021 Earnings Preview | N/A | |
| 2021-10-18 23:49 EST | News | Wave Life Sciences, Takeda amend CNS research collaboration | N/A | |
| 2021-10-18 23:49 EST | News | Takeda discontinues research with Wave for certain CNS programs; Wave to get $22.5M | N/A | |
| 2021-09-30 02:27 EST | News | Dosing underway in Wave Life's mid-stage WVE-N531 study in Duchenne muscular dystrophy | N/A | |
| 2021-09-29 03:19 EST | News | Wave Life Sciences falls after presentation on its RNA editing capability (Updated) | N/A | |
| 2021-09-09 14:39 EST | News | Wave Life Sciences gets dosing underway in early-stage Huntington’s disease trial | N/A | |
| 2021-08-17 03:33 EST | News | Wave Life Sciences Ltd. 2021 Q2 - Results - Earnings Call Presentation | N/A | |
| 2021-08-08 22:24 EST | News | Wave Life Sciences Ltd. (WVE) CEO Paul Bolno on Q2 2021 Results - Earnings Call Transcript | N/A | |
| 2021-08-05 16:13 EST | News | Wave Life Sciences EPS misses by $0.14, misses on revenue | N/A | |
| 2021-07-22 09:27 EST | News | Wave Life Sciences posts proof-of-concept data from genetic disorder study | N/A | |
| 2021-07-22 08:54 EST | News | Dosing underway in Wave Life Sciences' mid-stage WVE-004 study in neurodegenerative diseases | N/A | |
| 2021-03-29 20:19 EST | News | Wave Life Sciences falls on setback for Huntington’s disease trial (updated) | N/A | |
About Wave Life Sciences Ltd (WVE):
Wave Life Sciences Ltd., a clinical stage genetic medicine company, designs, optimizes, and produces of novel stereopure oligonucleotides through PRISM, a discovery and drug developing platform. The company is primarily developing oligonucleotides target ribonucleic acid to reduce the expression of disease-promoting proteins or transform the production of dysfunctional mutant proteins into the production of functional proteins. It develops WVE-120101 and WVE-120102, a stereopure therapeutic candidates, which are in Phase 1b/2a clinical trials for the treatment of Huntington's disease (HD); WVE-003, mutant huntingtin SNP3 program for the treatment of HD; WVE-004, C9orf72 program for the treatment of amyotrophic lateral sclerosis and frontotemporal dementia; WVE-N531, our Exon 53 program for the treatment of Duchenne muscular dystrophy; and ATXN3 program in SCA3. The company has collaboration agreements with Pfizer Inc., Takeda Pharmaceutical Company Limited, University of Oxford, and University of Massachusetts. Wave Life Sciences Ltd. was incorporated in 2012 and is based in Singapore.
General
- Name Wave Life Sciences Ltd
- Symbol WVE
- Type Common Stock
- Exchange NASDAQ
- Currency USD
- Country USA
- SectorHealthcare
- IndustryBiotechnology
- Full Time Employees 217
- Fiscal Year EndDecember
- IPO Date2015-11-11
- Gic SectorHealth Care
- Gic GroupPharmaceuticals, Biotechnology & Life Sciences
- Gic IndustryPharmaceuticals
- Gic SubIndustryPharmaceuticals
- Web URLhttp://www.wavelifesciences.com
View More
Valuation
- Price/Sales (Trailing 12 Mt.) 17.92
- Price/Book (Most Recent Quarter) 5.85
- Enterprise Value Revenue 16.38
View More
Financials
- Most Recent Quarter 2020-12-31
- Current Year EPS Estimate -$1.80
- Next Year EPS Estimate -$2.16
- Next Quarter EPS Estimate -$0.53
- Operating Margin -764%
- Return on Assets -34%
- Return on Equity -185%
- Revenue 20.08 million
- Earnings Per Share -$5.15
- Revenue Per Share $0.51
- Gross Profit -110867000
- Quarterly Earnings Growth 293.3%
View More
Highlights
- Market Capitalization 486.05 million
- EBITDA -173971008
- PE Ratio -10.65
- Analyst Target Price $16.86
- Book Value Per Share $1.70
View More
Share Statistics
- Shares Outstanding 49 million
- Shares Float 31.16 million
- % Held by Insiders 1297%
- % Held by Institutions 76.71%
- Shares Short 4.92 million
- Shares Short Prior Month 4.38 million
- Short Ratio 9.71
- Short % of Float 13%
- Short % of Shares Outstanding 10%
View More
Technicals
- Beta 0.37
- 52 Week High $19.98
- 52 Week Low $6.76
- 50 Day Moving Average 10.18
- 200 Day Moving Average 9.71
View More
Dividends
- Dividend Date N/A
- ExDividend Date N/A
- Dividend Yield 0%
View More
Wave Life Sciences Ltd (WVE) Dividend Calendar:
| Ex-Dividend Date | Payment Date | Record Date | Declared Date | Amount |
|---|
Wave Life Sciences Ltd (WVE) Earnings History:
Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.
| Quarter Date | Report Date | Actual Revenue | Reported EPS | EPS Estimate | Deviation from Estimate |
|---|---|---|---|---|---|
| 2020-12-31 | 2021-03-04 | $9.44 million | -$0.59 | -$0.60 | 2.14% |
| 2020-09-30 | 2020-11-09 | $N/A | -$0.86 | -$0.73 | -17.81% |
| 2020-06-30 | 2020-08-10 | $N/A | -$1.15 | -$1.07 | -7.48% |
| 2020-03-31 | 2020-05-11 | $4.16 million | -$1.38 | -$1.32 | -4.41% |
| 2019-12-31 | 2020-03-02 | $2.4 million | -$1.65 | -$1.46 | -13.35% |
| 2019-09-30 | 2019-11-05 | $2.93 million | -$1.48 | -$1.37 | -8.37% |
| 2019-06-30 | 2019-07-29 | $7.63 million | -$1.22 | -$1.00 | -22.31% |
| 2019-03-31 | 2019-05-10 | $3.03 million | -$1.36 | -$1.20 | -13.1% |
| 2018-12-31 | 2019-03-01 | $3.62 million | -$1.28 | -$1.25 | -2.81% |
| 2018-09-30 | 2018-11-09 | $4.49 million | -$1.28 | -$1.24 | -2.89% |
| 2018-06-30 | 2018-08-09 | $4.88 million | -$1.23 | -$1.10 | -11.56% |
| 2018-03-31 | 2018-05-09 | $1.42 million | -$1.26 | -$0.91 | -38.97% |
| 2017-12-31 | 2018-03-12 | $1.68 million | -$1.10 | -$1.04 | -5.43% |
| 2017-09-30 | 2017-11-09 | $1.32 million | -$0.94 | -$0.98 | 4.08% |
| 2017-06-30 | 2017-08-09 | $1.1 million | -$0.92 | -$0.81 | -13.23% |
| 2017-03-31 | 2017-05-10 | $383000 | -$0.89 | -$0.76 | -17.49% |
| 2016-12-31 | 2017-03-16 | $676000 | -$0.81 | -$0.67 | -20.45% |
| 2016-09-30 | 2016-11-09 | $392000 | -$0.75 | -$0.53 | -41.51% |
| 2016-06-30 | 2016-08-15 | $417000 | -$0.51 | -$0.37 | -37.84% |
| 2016-03-31 | 2016-05-16 | $N/A | -$0.36 | -$0.39 | 6.9% |
| 2015-12-31 | 2016-03-30 | $N/A | -$0.47 | -$0.32 | -46.88% |
| 2015-09-30 | 2015-11-11 | $26000 | -$0.54 | -$0.29 | -86.21% |
Wave Life Sciences Ltd (WVE) Company Financial Statements:
Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.
Income Statement:
| Date |
|---|
| Research Development |
| Income Before Tax |
| Selling General Administrative |
| Gross Profit |
| Ebit |
| Operating Income |
| Income Tax Expense |
| Total Revenue |
| Cost of Revenue |
| Total Other Income Expense Net |
| Net Income From Continuing Operations |
| Net Income Applicable to Common Shares |
Cash Flow:
| Date |
|---|
| Investments |
| Change to Liabilities |
| Total Cash Flow from Investing Activities |
| Net Borrowings |
| Total Cash Flow from Financial Activities |
| Change to Operating Activities |
| Change in Cash |
| Total Cash from Operating Activities |
| Depreciation |
| Other Cash Flow from Investing Activities |
| Change to Inventory |
| Change to Account Receivables |
| Other Cash Flow from Financing Activities |
| Change to Net Income |
| Capital Expenditures |
Balance Sheet:
| Date |
|---|
| Total Liabailities |
| Total Stockholder Equity |
| Other Current Liabilities |
| Total Assets |
| Common Stock |
| Other Current Assets |
| Retained Earnings |
| Other Liabilities |
| Other Assets |
| Cash |
| Total Current Liabilities |
| Other Stockholder Equity |
| Property, Plant & Equipment |
| Total Current Assets |
| Long Term Investments |
| Net Tangible Assets |
| Short Term Investments |
| Long Term Debt |
| Inventory |
| Accounts Payable |
Wave Life Sciences Ltd (WVE) Chart:
Wave Life Sciences Ltd (WVE) News:
Below you will find a list of latest news for Wave Life Sciences Ltd (WVE) from major news sources. You can filter the results to only show news from a specific source.
No recent news available
Wave Life Sciences Ltd (WVE) Options:
A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.
| Expiration Date | Strike | Last Price | Type | Volume | Open Interest | Implied Volatility | In The Money | Change | Change Percent |
|---|---|---|---|---|---|---|---|---|---|
| 2024-05-17 | 2.5 | 3.64 | CALL | 0 | 36 | 442.55 | TRUE | 0 | 0 |
| 2024-05-17 | 5 | 0.5 | CALL | 0 | 84 | 79.17 | TRUE | 0 | 0 |
| 2024-05-17 | 7.5 | 0.05 | CALL | 0 | 378 | 0 | FALSE | 0 | 0 |
| 2024-05-17 | 10 | 0.05 | CALL | 0 | 1 | 0 | FALSE | 0 | 0 |
| 2024-05-17 | 12.5 | 0 | CALL | 0 | 0 | 0 | FALSE | 0 | 0 |
| 2024-05-17 | 2.5 | 0.15 | PUT | 0 | 25 | 0 | FALSE | 0 | 0 |
| 2024-05-17 | 5 | 0.3 | PUT | 30 | 58 | 94.57 | FALSE | 0.3 | 0 |
| 2024-05-17 | 7.5 | 1.82 | PUT | 0 | 0 | 341.4 | TRUE | 0 | 0 |
| 2024-05-17 | 10 | 0 | PUT | 0 | 0 | 433.07 | TRUE | 0 | 0 |
| 2024-05-17 | 12.5 | 0 | PUT | 0 | 0 | 465.42 | TRUE | 0 | 0 |
| 2024-06-21 | 2.5 | 0 | CALL | 0 | 0 | 98.24 | TRUE | 0 | 0 |
| 2024-06-21 | 5 | 0 | CALL | 0 | 0 | 79.66 | TRUE | 0 | 0 |
| 2024-06-21 | 7.5 | 0 | CALL | 0 | 0 | 86.09 | FALSE | 0 | 0 |
| 2024-06-21 | 10 | 0 | CALL | 0 | 0 | 0 | FALSE | 0 | 0 |
| 2024-06-21 | 2.5 | 0 | PUT | 0 | 0 | 0 | FALSE | 0 | 0 |
| 2024-06-21 | 5 | 0.65 | PUT | 30 | 20 | 86.03 | FALSE | 0.65 | 0 |
| 2024-06-21 | 7.5 | 0 | PUT | 0 | 0 | 221.66 | TRUE | 0 | 0 |
| 2024-06-21 | 10 | 0 | PUT | 0 | 0 | 228.05 | TRUE | 0 | 0 |
| 2024-07-19 | 2.5 | 3.63 | CALL | 0 | 6 | 233 | TRUE | 0 | 0 |
| 2024-07-19 | 5 | 0.65 | CALL | 0 | 467 | 77.5 | TRUE | 0 | 0 |
| 2024-07-19 | 7.5 | 0.24 | CALL | 0 | 756 | 77.91 | FALSE | 0 | 0 |
| 2024-07-19 | 10 | 0.09 | CALL | 0 | 184 | 95.64 | FALSE | 0 | 0 |
| 2024-07-19 | 12.5 | 0 | CALL | 0 | 0 | 0 | FALSE | 0 | 0 |
| 2024-07-19 | 15 | 0 | CALL | 0 | 0 | 0 | FALSE | 0 | 0 |
| 2024-07-19 | 2.5 | 0.13 | PUT | 0 | 14 | 0 | FALSE | 0 | 0 |
| 2024-07-19 | 5 | 0.75 | PUT | 0 | 84 | 74.12 | FALSE | 0 | 0 |
| 2024-07-19 | 7.5 | 2.23 | PUT | 0 | 9 | 152.17 | TRUE | 0 | 0 |
| 2024-07-19 | 10 | 0 | PUT | 0 | 0 | 167.09 | TRUE | 0 | 0 |
| 2024-07-19 | 12.5 | 0 | PUT | 0 | 0 | 175.92 | TRUE | 0 | 0 |
| 2024-07-19 | 15 | 0 | PUT | 0 | 0 | 196.92 | TRUE | 0 | 0 |
| 2024-10-18 | 2.5 | 2.6 | CALL | 0 | 1 | 196.51 | TRUE | 0 | 0 |
| 2024-10-18 | 5 | 1.2 | CALL | 4 | 118 | 83.67 | TRUE | -0.02 | -0.02 |
| 2024-10-18 | 7.5 | 0.5 | CALL | 35 | 319 | 81.04 | FALSE | -0.05 | -0.09 |
| 2024-10-18 | 10 | 0.25 | CALL | 2 | 448 | 83.89 | FALSE | 0.25 | 0 |
| 2024-10-18 | 12.5 | 0.3 | CALL | 0 | 5 | 87.95 | FALSE | 0 | 0 |
| 2024-10-18 | 15 | 0.2 | CALL | 0 | 2 | 0 | FALSE | 0 | 0 |
| 2024-10-18 | 2.5 | 0.25 | PUT | 0 | 122 | 103.32 | FALSE | 0 | 0 |
| 2024-10-18 | 5 | 1.15 | PUT | 0 | 16 | 79.95 | FALSE | 0 | 0 |
| 2024-10-18 | 7.5 | 2.75 | PUT | 0 | 34 | 81.4 | TRUE | 0 | 0 |
| 2024-10-18 | 10 | 0 | PUT | 0 | 0 | 159.5 | TRUE | 0 | 0 |
| 2024-10-18 | 12.5 | 5.7 | PUT | 0 | 2 | 129.55 | TRUE | 0 | 0 |
| 2024-10-18 | 15 | 0 | PUT | 0 | 0 | 185.93 | TRUE | 0 | 0 |
Latest WVE Trades:
| Date | Shares | Price |
|---|---|---|
| Jun 13, 2022 7:59 PM EST | 17 | $1.995 |
| Jun 13, 2022 7:59 PM EST | 100 | $2 |
| Jun 13, 2022 7:59 PM EST | 17 | $1.995 |
| Jun 13, 2022 7:59 PM EST | 17 | $1.995 |
| Jun 13, 2022 7:59 PM EST | 100 | $1.995 |
Wave Life Sciences Ltd (WVE) SEC Filings:
An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.
| Date | Form Type | Form Name | Link |
|---|---|---|---|
| 2020-07-02 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1631574/000089924320018398/0000899243-20-018398-index.htm |
| 2019-08-09 | UPLOAD | SEC-generated letter | https://www.sec.gov/Archives/edgar/data/1631574/000000000019012261/0000000000-19-012261-index.htm |
| 2019-11-27 | UPLOAD | SEC-generated letter | https://www.sec.gov/Archives/edgar/data/1631574/000000000019015921/0000000000-19-015921-index.htm |
| 2019-12-06 | UPLOAD | SEC-generated letter | https://www.sec.gov/Archives/edgar/data/1631574/000000000019016177/0000000000-19-016177-index.htm |
| 2019-02-14 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1631574/000008025519002715/0000080255-19-002715-index.htm |
| 2020-02-14 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1631574/000008025520001311/0000080255-20-001311-index.htm |
| 2019-02-08 | SC 13G | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1631574/000021545719006909/0000215457-19-006909-index.htm |
| 2019-03-08 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1631574/000021545719007594/0000215457-19-007594-index.htm |
| 2020-02-07 | SC 13G | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1631574/000083423720008192/0000834237-20-008192-index.htm |
| 2020-08-24 | SC 13G | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1631574/000089542120000470/0000895421-20-000470-index.htm |
| 2018-08-15 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1631574/000089924318022514/0000899243-18-022514-index.htm |
| 2018-08-15 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1631574/000089924318022515/0000899243-18-022515-index.htm |
| 2018-09-26 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1631574/000089924318025318/0000899243-18-025318-index.htm |
| 2018-09-26 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1631574/000089924318025320/0000899243-18-025320-index.htm |
| 2018-09-26 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1631574/000089924318025322/0000899243-18-025322-index.htm |
| 2018-11-16 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1631574/000089924318029157/0000899243-18-029157-index.htm |
| 2019-02-21 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1631574/000089924319004460/0000899243-19-004460-index.htm |
| 2019-02-21 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1631574/000089924319004462/0000899243-19-004462-index.htm |
| 2019-02-21 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1631574/000089924319004464/0000899243-19-004464-index.htm |
| 2019-02-21 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1631574/000089924319004466/0000899243-19-004466-index.htm |
| 2019-02-21 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1631574/000089924319004467/0000899243-19-004467-index.htm |
| 2019-03-11 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1631574/000089924319007106/0000899243-19-007106-index.htm |
| 2019-03-11 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1631574/000089924319007110/0000899243-19-007110-index.htm |
| 2019-03-11 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1631574/000089924319007112/0000899243-19-007112-index.htm |
| 2019-03-11 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1631574/000089924319007113/0000899243-19-007113-index.htm |
| 2019-03-11 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1631574/000089924319007114/0000899243-19-007114-index.htm |
| 2019-03-19 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1631574/000089924319008404/0000899243-19-008404-index.htm |
| 2019-07-09 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1631574/000089924319019395/0000899243-19-019395-index.htm |
| 2019-08-07 | 3 | Initial statement of beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1631574/000089924319021292/0000899243-19-021292-index.htm |
| 2019-08-07 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1631574/000089924319021293/0000899243-19-021293-index.htm |
| 2019-08-16 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1631574/000089924319021959/0000899243-19-021959-index.htm |
| 2019-08-16 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1631574/000089924319021962/0000899243-19-021962-index.htm |
| 2019-08-16 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1631574/000089924319021963/0000899243-19-021963-index.htm |
| 2019-08-16 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1631574/000089924319021965/0000899243-19-021965-index.htm |
| 2019-08-16 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1631574/000089924319021966/0000899243-19-021966-index.htm |
| 2019-08-16 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1631574/000089924319021967/0000899243-19-021967-index.htm |
| 2019-09-06 | 3 | Initial statement of beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1631574/000089924319023028/0000899243-19-023028-index.htm |
| 2019-09-06 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1631574/000089924319023032/0000899243-19-023032-index.htm |
| 2019-09-06 | 3 | Initial statement of beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1631574/000089924319023033/0000899243-19-023033-index.htm |
| 2019-09-06 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1631574/000089924319023034/0000899243-19-023034-index.htm |
| 2019-09-06 | 3 | Initial statement of beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1631574/000089924319023035/0000899243-19-023035-index.htm |
| 2019-09-06 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1631574/000089924319023038/0000899243-19-023038-index.htm |
| 2019-11-22 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1631574/000089924319027985/0000899243-19-027985-index.htm |
| 2019-12-05 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1631574/000089924319028606/0000899243-19-028606-index.htm |
| 2020-01-17 | 3 | Initial statement of beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1631574/000089924320001393/0000899243-20-001393-index.htm |
| 2020-02-05 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1631574/000089924320003379/0000899243-20-003379-index.htm |
| 2020-02-20 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1631574/000089924320005342/0000899243-20-005342-index.htm |
| 2020-02-20 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1631574/000089924320005346/0000899243-20-005346-index.htm |
| 2020-02-20 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1631574/000089924320005349/0000899243-20-005349-index.htm |
| 2020-02-20 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1631574/000089924320005351/0000899243-20-005351-index.htm |
| 2020-03-05 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1631574/000089924320007277/0000899243-20-007277-index.htm |
| 2020-03-05 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1631574/000089924320007281/0000899243-20-007281-index.htm |
| 2020-03-05 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1631574/000089924320007282/0000899243-20-007282-index.htm |
| 2020-03-05 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1631574/000089924320007284/0000899243-20-007284-index.htm |
| 2020-03-05 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1631574/000089924320007285/0000899243-20-007285-index.htm |
| 2020-07-02 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1631574/000089924320018398/0000899243-20-018398-index.htm |
| 2020-08-20 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1631574/000089924320023078/0000899243-20-023078-index.htm |
| 2020-08-20 | 3 | Initial statement of beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1631574/000089924320023079/0000899243-20-023079-index.htm |
| 2020-08-20 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1631574/000089924320023080/0000899243-20-023080-index.htm |
| 2020-08-20 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1631574/000089924320023085/0000899243-20-023085-index.htm |
| 2020-08-20 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1631574/000089924320023086/0000899243-20-023086-index.htm |
| 2020-08-20 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1631574/000089924320023087/0000899243-20-023087-index.htm |
| 2020-08-20 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1631574/000089924320023088/0000899243-20-023088-index.htm |
| 2020-08-20 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1631574/000089924320023089/0000899243-20-023089-index.htm |
| 2020-08-20 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1631574/000089924320023092/0000899243-20-023092-index.htm |
| 2020-08-20 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1631574/000089924320023093/0000899243-20-023093-index.htm |
| 2020-08-27 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1631574/000089924320023540/0000899243-20-023540-index.htm |
| 2020-09-17 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1631574/000089924320025614/0000899243-20-025614-index.htm |
| 2020-01-28 | SC 13G | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1631574/000090221920000204/0000902219-20-000204-index.htm |
| 2020-02-14 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1631574/000110465920021834/0001104659-20-021834-index.htm |
| 2019-01-28 | SC 13D/A | General statement of acquisition of beneficial ownership | https://www.sec.gov/Archives/edgar/data/1631574/000114420419003157/0001144204-19-003157-index.htm |
| 2019-01-28 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1631574/000114420419003160/0001144204-19-003160-index.htm |
| 2019-02-14 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1631574/000114420419008078/0001144204-19-008078-index.htm |
| 2018-09-11 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1631574/000119312518270464/0001193125-18-270464-index.htm |
| 2018-10-02 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1631574/000119312518290300/0001193125-18-290300-index.htm |
| 2018-10-03 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1631574/000119312518291962/0001193125-18-291962-index.htm |
| 2018-10-09 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1631574/000119312518295345/0001193125-18-295345-index.htm |
| 2018-11-09 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1631574/000119312518323137/0001193125-18-323137-index.htm |
| 2018-11-09 | S-8 | Securities to be offered to employees in employee benefit plans | https://www.sec.gov/Archives/edgar/data/1631574/000119312518323760/0001193125-18-323760-index.htm |
| 2018-12-06 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1631574/000119312518342992/0001193125-18-342992-index.htm |
| 2019-01-03 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1631574/000119312519001144/0001193125-19-001144-index.htm |
| 2019-01-23 | 424B5 | Prospectus [Rule 424(b)(5)] | https://www.sec.gov/Archives/edgar/data/1631574/000119312519014851/0001193125-19-014851-index.htm |
| 2019-01-23 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1631574/000119312519014884/0001193125-19-014884-index.htm |
| 2019-01-24 | 424B5 | Prospectus [Rule 424(b)(5)] | https://www.sec.gov/Archives/edgar/data/1631574/000119312519015961/0001193125-19-015961-index.htm |
| 2019-01-24 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1631574/000119312519015976/0001193125-19-015976-index.htm |
| 2019-02-14 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1631574/000119312519040844/0001193125-19-040844-index.htm |
| 2019-02-20 | SC 13D/A | General statement of acquisition of beneficial ownership | https://www.sec.gov/Archives/edgar/data/1631574/000119312519045277/0001193125-19-045277-index.htm |
| 2019-03-01 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1631574/000119312519059251/0001193125-19-059251-index.htm |
| 2019-03-14 | SC 13D/A | General statement of acquisition of beneficial ownership | https://www.sec.gov/Archives/edgar/data/1631574/000119312519074933/0001193125-19-074933-index.htm |
| 2019-04-16 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1631574/000119312519107259/0001193125-19-107259-index.htm |
| 2019-04-29 | 10-K/A | Annual report [Section 13 and 15(d), not S-K Item 405] | https://www.sec.gov/Archives/edgar/data/1631574/000119312519125660/0001193125-19-125660-index.htm |
| 2019-05-10 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1631574/000119312519143674/0001193125-19-143674-index.htm |
| 2019-05-10 | S-3ASR | Automatic shelf registration statement of securities of well-known seasoned issuers | https://www.sec.gov/Archives/edgar/data/1631574/000119312519144278/0001193125-19-144278-index.htm |
| 2019-06-05 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1631574/000119312519165571/0001193125-19-165571-index.htm |
| 2019-06-26 | DEF 14A | Other definitive proxy statements | https://www.sec.gov/Archives/edgar/data/1631574/000119312519182697/0001193125-19-182697-index.htm |
| 2019-07-29 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1631574/000119312519205421/0001193125-19-205421-index.htm |
| 2019-08-06 | S-3 | Registration statement under Securities Act of 1933 | https://www.sec.gov/Archives/edgar/data/1631574/000119312519214152/0001193125-19-214152-index.htm |
| 2019-08-06 | S-8 | Securities to be offered to employees in employee benefit plans | https://www.sec.gov/Archives/edgar/data/1631574/000119312519214169/0001193125-19-214169-index.htm |
| 2019-08-12 | CORRESP | Correspondence | https://www.sec.gov/Archives/edgar/data/1631574/000119312519218981/0001193125-19-218981-index.htm |
| 2019-08-14 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1631574/000119312519221246/0001193125-19-221246-index.htm |
| 2019-08-16 | 8-K/A | Current report | https://www.sec.gov/Archives/edgar/data/1631574/000119312519223468/0001193125-19-223468-index.htm |
| 2019-09-05 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1631574/000119312519238229/0001193125-19-238229-index.htm |
| 2019-10-07 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1631574/000119312519263797/0001193125-19-263797-index.htm |
| 2019-11-05 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1631574/000119312519284729/0001193125-19-284729-index.htm |
| 2019-11-05 | S-8 | Securities to be offered to employees in employee benefit plans | https://www.sec.gov/Archives/edgar/data/1631574/000119312519284817/0001193125-19-284817-index.htm |
| 2019-12-03 | CORRESP | Correspondence | https://www.sec.gov/Archives/edgar/data/1631574/000119312519304738/0001193125-19-304738-index.htm |
| 2019-12-16 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1631574/000119312519314469/0001193125-19-314469-index.htm |
| 2019-12-23 | SC 13G | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1631574/000119312519322733/0001193125-19-322733-index.htm |
| 2019-12-30 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1631574/000119312519325442/0001193125-19-325442-index.htm |
| 2020-01-10 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1631574/000119312520005483/0001193125-20-005483-index.htm |
| 2020-01-13 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1631574/000119312520005882/0001193125-20-005882-index.htm |
| 2020-02-06 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1631574/000119312520026760/0001193125-20-026760-index.htm |
| 2020-02-14 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1631574/000119312520037841/0001193125-20-037841-index.htm |
| 2020-02-14 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1631574/000119312520038291/0001193125-20-038291-index.htm |
| 2020-03-02 | POSASR | Post-effective Amendment to an automatic shelf registration statement | https://www.sec.gov/Archives/edgar/data/1631574/000119312520057766/0001193125-20-057766-index.htm |
| 2020-03-02 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1631574/000119312520057791/0001193125-20-057791-index.htm |
| 2020-03-02 | POS AM | Post-Effective amendments for registration statement | https://www.sec.gov/Archives/edgar/data/1631574/000119312520057905/0001193125-20-057905-index.htm |
| 2020-04-14 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1631574/000119312520107212/0001193125-20-107212-index.htm |
| 2020-04-23 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1631574/000119312520117339/0001193125-20-117339-index.htm |
| 2020-05-11 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1631574/000119312520138276/0001193125-20-138276-index.htm |
| 2020-06-26 | DEF 14A | Other definitive proxy statements | https://www.sec.gov/Archives/edgar/data/1631574/000119312520181069/0001193125-20-181069-index.htm |
| 2020-08-10 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1631574/000119312520214106/0001193125-20-214106-index.htm |
| 2020-08-10 | S-8 | Securities to be offered to employees in employee benefit plans | https://www.sec.gov/Archives/edgar/data/1631574/000119312520214144/0001193125-20-214144-index.htm |
| 2020-08-10 | S-8 | Securities to be offered to employees in employee benefit plans | https://www.sec.gov/Archives/edgar/data/1631574/000119312520214223/0001193125-20-214223-index.htm |
| 2020-08-18 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1631574/000119312520223731/0001193125-20-223731-index.htm |
| 2020-08-19 | 8-K/A | Current report | https://www.sec.gov/Archives/edgar/data/1631574/000119312520224764/0001193125-20-224764-index.htm |
| 2020-08-25 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1631574/000119312520229903/0001193125-20-229903-index.htm |
| 2020-09-09 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1631574/000119312520241608/0001193125-20-241608-index.htm |
| 2020-09-22 | 424B5 | Prospectus [Rule 424(b)(5)] | https://www.sec.gov/Archives/edgar/data/1631574/000119312520251261/0001193125-20-251261-index.htm |
| 2020-09-22 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1631574/000119312520251297/0001193125-20-251297-index.htm |
| 2020-09-23 | 424B5 | Prospectus [Rule 424(b)(5)] | https://www.sec.gov/Archives/edgar/data/1631574/000119312520252307/0001193125-20-252307-index.htm |
| 2020-09-23 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1631574/000119312520252347/0001193125-20-252347-index.htm |
| 2020-09-25 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1631574/000119312520254552/0001193125-20-254552-index.htm |
| 2020-10-01 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1631574/000119312520260543/0001193125-20-260543-index.htm |
| 2019-02-13 | SC 13G | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1631574/000127417319000113/0001274173-19-000113-index.htm |
| 2019-08-09 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1631574/000127417319000120/0001274173-19-000120-index.htm |
| 2020-01-10 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1631574/000127417320000004/0001274173-20-000004-index.htm |
| 2020-01-21 | SC 13G | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1631574/000149315220000835/0001493152-20-000835-index.htm |
| 2018-11-09 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1631574/000156459018028757/0001564590-18-028757-index.htm |
| 2019-03-01 | 10-K | Annual report [Section 13 and 15(d), not S-K Item 405] | https://www.sec.gov/Archives/edgar/data/1631574/000156459019005671/0001564590-19-005671-index.htm |
| 2019-05-10 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1631574/000156459019018521/0001564590-19-018521-index.htm |
| 2019-08-06 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1631574/000156459019029396/0001564590-19-029396-index.htm |
| 2019-11-05 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1631574/000156459019040431/0001564590-19-040431-index.htm |
| 2020-03-02 | 10-K | Annual report [Section 13 and 15(d), not S-K Item 405] | https://www.sec.gov/Archives/edgar/data/1631574/000156459020007972/0001564590-20-007972-index.htm |
| 2020-04-29 | 10-K/A | Annual report [Section 13 and 15(d), not S-K Item 405] | https://www.sec.gov/Archives/edgar/data/1631574/000156459020019772/0001564590-20-019772-index.htm |
| 2020-05-11 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1631574/000156459020023860/0001564590-20-023860-index.htm |
| 2020-08-10 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1631574/000156459020038620/0001564590-20-038620-index.htm |
| 2019-08-14 | EFFECT | Notice of Effectiveness | https://www.sec.gov/Archives/edgar/data/1631574/999999999519001883/9999999995-19-001883-index.htm |
| 2020-05-01 | EFFECT | Notice of Effectiveness | https://www.sec.gov/Archives/edgar/data/1631574/999999999520000974/9999999995-20-000974-index.htm |
| 2018-09-17 | CT ORDER | Confidential treatment order | https://www.sec.gov/Archives/edgar/data/1631574/999999999718007937/9999999997-18-007937-index.htm |
Wave Life Sciences Ltd (WVE) Insider Transactions:
Here you will find a list of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Wave Life Sciences Ltd (WVE). Company insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.Insider Ownership: 1297%Institutional Ownership: 7671%
| Transaction Date | Insider Name | Insider Title | Type | Shares Number | Shares Price | Total Transaction | Shares Held After Transaction | Link |
|---|---|---|---|---|---|---|---|---|
| 2019-02-19 | Keith Regnante | Chief Financial Officer | Sell | 1,298.00 | 36.84 | 47,817.80 | 15,686.00 | https://www.sec.gov/Archives/edgar/data/1631574/000089924319004467/0000899243-19-004467-index.htm |
| 2018-09-24 | Keith Regnante | Chief Financial Officer | Sell | 29,500.00 | 55.00 | 1,622,500.00 | 16,984.00 | https://www.sec.gov/Archives/edgar/data/1631574/000089924318025320/0000899243-18-025320-index.htm |
| 2019-02-19 | Chris Francis | Officer | Sell | 1,709.00 | 36.84 | 62,959.05 | 20,368.00 | https://www.sec.gov/Archives/edgar/data/1631574/000089924319004460/0000899243-19-004460-index.htm |
| 2018-09-24 | Chris Francis | Officer | Sell | 1,032.00 | 56.00 | 57,792.00 | 22,077.00 | https://www.sec.gov/Archives/edgar/data/1631574/000089924318025322/0000899243-18-025322-index.htm |
| 2018-09-25 | Chris Francis | Officer | Sell | 10,543.00 | 56.00 | 590,408.00 | 22,077.00 | https://www.sec.gov/Archives/edgar/data/1631574/000089924318025322/0000899243-18-025322-index.htm |
| 2018-09-24 | Chris Francis | Officer | Buy | 1,032.00 | 2.48 | 2,559.36 | 23,109.00 | https://www.sec.gov/Archives/edgar/data/1631574/000089924318025322/0000899243-18-025322-index.htm |
| 2019-02-19 | Chandra Vargeese | Senior VP, Drug Discovery | Sell | 2,055.00 | 36.84 | 75,706.20 | 25,245.00 | https://www.sec.gov/Archives/edgar/data/1631574/000089924319004462/0000899243-19-004462-index.htm |
| 2019-02-19 | PAUL BOLNO | President and CEO | Sell | 119.00 | 37.47 | 4,458.45 | 271,209.00 | https://www.sec.gov/Archives/edgar/data/1631574/000089924319004464/0000899243-19-004464-index.htm |
| 2019-02-19 | PAUL BOLNO | President and CEO | Sell | 7,614.00 | 36.38 | 276,997.32 | 271,328.00 | https://www.sec.gov/Archives/edgar/data/1631574/000089924319004464/0000899243-19-004464-index.htm |
| 2020-07-02 | PAUL BOLNO | President and CEO | Sell | 43,068.00 | 10.26 | 441,877.68 | 272,181.00 | https://www.sec.gov/Archives/edgar/data/1631574/000089924320018398/0000899243-20-018398-index.htm |
| 2020-07-02 | PAUL BOLNO | President and CEO | Sell | 95,921.00 | 10.27 | 985,108.67 | 272,181.00 | https://www.sec.gov/Archives/edgar/data/1631574/000089924320018398/0000899243-20-018398-index.htm |
| 2020-08-25 | PAUL BOLNO | President and CEO | Sell | 25,000.00 | 12.00 | 300,000.00 | 272,181.00 | https://www.sec.gov/Archives/edgar/data/1631574/000089924320023540/0000899243-20-023540-index.htm |
| 2020-09-15 | PAUL BOLNO | President and CEO | Sell | 100,000.00 | 15.00 | 1,500,000.00 | 272,181.00 | https://www.sec.gov/Archives/edgar/data/1631574/000089924320025614/0000899243-20-025614-index.htm |
| 2018-09-24 | Chandra Vargeese | Senior VP, Drug Discovery | Sell | 3,000.00 | 55.00 | 165,000.00 | 27,300.00 | https://www.sec.gov/Archives/edgar/data/1631574/000089924318025318/0000899243-18-025318-index.htm |
| 2019-03-07 | Keith Regnante | Chief Financial Officer | Buy | 13,500.00 | 29,186.00 | https://www.sec.gov/Archives/edgar/data/1631574/000089924319007114/0000899243-19-007114-index.htm | ||
| 2020-08-25 | PAUL BOLNO | President and CEO | Buy | 25,000.00 | 2.48 | 62,000.00 | 297,181.00 | https://www.sec.gov/Archives/edgar/data/1631574/000089924320023540/0000899243-20-023540-index.htm |
| 2019-11-20 | Gregory L. Verdine | Director | Sell | 2,609.00 | 32.74 | 85,418.66 | 30,000.00 | https://www.sec.gov/Archives/edgar/data/1631574/000089924319027985/0000899243-19-027985-index.htm |
| 2018-09-24 | Chandra Vargeese | Senior VP, Drug Discovery | Buy | 3,000.00 | 2.48 | 7,440.00 | 30,300.00 | https://www.sec.gov/Archives/edgar/data/1631574/000089924318025318/0000899243-18-025318-index.htm |
| 2020-02-18 | Chris Francis | Officer | Sell | 2,708.00 | 7.85 | 21,257.80 | 31,160.00 | https://www.sec.gov/Archives/edgar/data/1631574/000089924320005346/0000899243-20-005346-index.htm |
| 2020-07-02 | PAUL BOLNO | President and CEO | Sell | 4,509.00 | 10.82 | 48,787.38 | 315,249.00 | https://www.sec.gov/Archives/edgar/data/1631574/000089924320018398/0000899243-20-018398-index.htm |
| 2020-02-18 | PAUL BOLNO | President and CEO | Sell | 11,451.00 | 7.85 | 89,890.35 | 319,758.00 | https://www.sec.gov/Archives/edgar/data/1631574/000089924320005349/0000899243-20-005349-index.htm |
| 2019-11-20 | Gregory L. Verdine | Director | Sell | 3,400.00 | 31.59 | 107,406.00 | 32,609.00 | https://www.sec.gov/Archives/edgar/data/1631574/000089924319027985/0000899243-19-027985-index.htm |
| 2018-09-25 | Chris Francis | Officer | Buy | 10,543.00 | 2.48 | 26,146.64 | 32,620.00 | https://www.sec.gov/Archives/edgar/data/1631574/000089924318025322/0000899243-18-025322-index.htm |
| 2019-03-07 | PAUL BOLNO | President and CEO | Buy | 60,000.00 | 331,209.00 | https://www.sec.gov/Archives/edgar/data/1631574/000089924319007112/0000899243-19-007112-index.htm | ||
| 2019-03-15 | PAUL BOLNO | President and CEO | Sell | 1,763.00 | 46.00 | 81,098.00 | 331,209.00 | https://www.sec.gov/Archives/edgar/data/1631574/000089924319008404/0000899243-19-008404-index.htm |
| 2019-03-15 | PAUL BOLNO | President and CEO | Sell | 8,237.00 | 45.22 | 372,477.14 | 332,972.00 | https://www.sec.gov/Archives/edgar/data/1631574/000089924319008404/0000899243-19-008404-index.htm |
| 2019-03-07 | Chris Francis | Officer | Buy | 13,500.00 | 33,868.00 | https://www.sec.gov/Archives/edgar/data/1631574/000089924319007110/0000899243-19-007110-index.htm | ||
| 2019-03-15 | PAUL BOLNO | President and CEO | Sell | 5,065.00 | 45.89 | 232,432.85 | 341,209.00 | https://www.sec.gov/Archives/edgar/data/1631574/000089924319008404/0000899243-19-008404-index.htm |
| 2019-03-15 | PAUL BOLNO | President and CEO | Sell | 34,935.00 | 45.45 | 1,587,795.75 | 346,274.00 | https://www.sec.gov/Archives/edgar/data/1631574/000089924319008404/0000899243-19-008404-index.htm |
| 2019-08-05 | Mark Baldry | Chief Commerical Officer | Buy | 35,000.00 | 35,000.00 | https://www.sec.gov/Archives/edgar/data/1631574/000089924319021293/0000899243-19-021293-index.htm | ||
| 2019-11-20 | Gregory L. Verdine | Director | Sell | 24,030.00 | 30.27 | 727,388.10 | 36,009.00 | https://www.sec.gov/Archives/edgar/data/1631574/000089924319027985/0000899243-19-027985-index.htm |
| 2020-07-02 | PAUL BOLNO | President and CEO | Sell | 4,079.00 | 10.91 | 44,501.89 | 368,102.00 | https://www.sec.gov/Archives/edgar/data/1631574/000089924320018398/0000899243-20-018398-index.htm |
| 2020-02-18 | Chandra Vargeese | Senior VP, Drug Discovery | Sell | 3,188.00 | 7.85 | 25,025.80 | 37,057.00 | https://www.sec.gov/Archives/edgar/data/1631574/000089924320005342/0000899243-20-005342-index.htm |
| 2020-07-02 | PAUL BOLNO | President and CEO | Buy | 100,000.00 | 2.48 | 248,000.00 | 372,181.00 | https://www.sec.gov/Archives/edgar/data/1631574/000089924320018398/0000899243-20-018398-index.htm |
| 2020-09-15 | PAUL BOLNO | President and CEO | Buy | 100,000.00 | 2.48 | 248,000.00 | 372,181.00 | https://www.sec.gov/Archives/edgar/data/1631574/000089924320025614/0000899243-20-025614-index.htm |
| 2019-02-19 | Michael A. Panzara | Franchise Lead, Neurology | Sell | 1,837.00 | 36.84 | 67,673.98 | 37,388.00 | https://www.sec.gov/Archives/edgar/data/1631574/000089924319004466/0000899243-19-004466-index.htm |
| 2019-03-15 | PAUL BOLNO | President and CEO | Buy | 50,000.00 | 2.48 | 124,000.00 | 381,209.00 | https://www.sec.gov/Archives/edgar/data/1631574/000089924319008404/0000899243-19-008404-index.htm |
| 2019-08-05 | Mark Baldry | Chief Commerical Officer | Buy | 4,000.00 | 39,000.00 | https://www.sec.gov/Archives/edgar/data/1631574/000089924319021293/0000899243-19-021293-index.htm | ||
| 2020-02-18 | Michael A. Panzara | Chief Medical Officer | Sell | 2,981.00 | 7.85 | 23,400.85 | 39,349.00 | https://www.sec.gov/Archives/edgar/data/1631574/000089924320005351/0000899243-20-005351-index.htm |
| 2019-03-07 | Chandra Vargeese | Senior VP, Drug Discovery | Buy | 15,000.00 | 40,245.00 | https://www.sec.gov/Archives/edgar/data/1631574/000089924319007106/0000899243-19-007106-index.htm | ||
| 2019-12-03 | Chandra Vargeese | Senior VP, Drug Discovery | Sell | 6,000.00 | 35.00 | 210,000.00 | 40,245.00 | https://www.sec.gov/Archives/edgar/data/1631574/000089924319028606/0000899243-19-028606-index.htm |
| 2019-07-05 | Michael A. Panzara | Chief Medical Officer | Sell | 445.00 | 27.26 | 12,130.70 | 42,330.00 | https://www.sec.gov/Archives/edgar/data/1631574/000089924319019395/0000899243-19-019395-index.htm |
| 2019-07-05 | Michael A. Panzara | Chief Medical Officer | Sell | 2,613.00 | 26.88 | 70,237.44 | 42,775.00 | https://www.sec.gov/Archives/edgar/data/1631574/000089924319019395/0000899243-19-019395-index.htm |
| 2019-03-11 | Michael A. Panzara | Franchise Lead, Neurology | Sell | 7,000.00 | 48.00 | 336,000.00 | 45,388.00 | https://www.sec.gov/Archives/edgar/data/1631574/000089924319007113/0000899243-19-007113-index.htm |
| 2019-12-03 | Chandra Vargeese | Senior VP, Drug Discovery | Buy | 6,000.00 | 2.48 | 14,880.00 | 46,245.00 | https://www.sec.gov/Archives/edgar/data/1631574/000089924319028606/0000899243-19-028606-index.htm |
| 2018-09-24 | Keith Regnante | Chief Financial Officer | Buy | 29,500.00 | 20.89 | 616,255.00 | 46,484.00 | https://www.sec.gov/Archives/edgar/data/1631574/000089924318025320/0000899243-18-025320-index.htm |
| 2019-03-07 | Michael A. Panzara | Franchise Lead, Neurology | Buy | 15,000.00 | 52,388.00 | https://www.sec.gov/Archives/edgar/data/1631574/000089924319007113/0000899243-19-007113-index.htm | ||
| 2018-11-14 | Gregory L. Verdine | Director | Sell | 4,300.00 | 39.52 | 169,936.00 | 60,039.00 | https://www.sec.gov/Archives/edgar/data/1631574/000089924318029157/0000899243-18-029157-index.htm |
| 2020-02-03 | David G Gaiero | Interim CFO | Sell | 651.00 | 7.00 | 4,557.00 | 6,392.00 | https://www.sec.gov/Archives/edgar/data/1631574/000089924320003379/0000899243-20-003379-index.htm |
| 2018-11-14 | Gregory L. Verdine | Director | Sell | 10,700.00 | 38.59 | 412,913.00 | 64,339.00 | https://www.sec.gov/Archives/edgar/data/1631574/000089924318029157/0000899243-18-029157-index.htm |
| 2019-01-24 | RA CAPITAL MANAGEMENT, LLC | Director | Buy | 263,158.00 | 38.00 | 10,000,004.00 | 7,775,207.00 | https://www.sec.gov/Archives/edgar/data/1631574/000114420419003160/0001144204-19-003160-index.htm |